ObvioHealth Q&A: connecting DCT dots with remote tech
The move towards decentralised clinical trials has been accelerated by Covid-19, and the tech that underpins remote trials is evolving…
ByFocus box
AD/PD 2021: Biogen could enable efficient patient screening for both clinical trials and clinical practice in Alzheimer’s disease
During the Aβ targeting therapies symposium at this month's International Virtual Conference on Alzheimer’s disease and Parkinson’s disease (AD/PD 2021),…
By
J&J’s single-shot Covid-19 vaccine: the journey to approval
J&J’s single-shot Covid-19 vaccine has received emergency authorisation in both the US and EU. What has been the vaccine candidate’s…
By
Q&A with N-SIDE’s Sébastien Coppe: how digitisation overcomes clinical bottlenecks
The Covid-19 pandemic has transformed clinical development. Rather than taking ten years to bring a drug to market, vaccine manufacturers…
By
Inactivated SARS-CoV-2 vaccines unlikely candidates for undercutting spike-mutation variants of concern
Despite the theoretical potential of inactivated virus vaccines to offer a lead over other Covid-19 vaccine technologies against variants of…
By
New SARS-CoV-2 variants push Covid-19 vaccine long-term durability questions to back seat
Long-term Covid-19 vaccine durability has become less of an endgame since it has become increasingly likely additional shots will be…
By
Trial resumptions slowing due to new Covid-19 strains
Since early March 2020, more than 500 companies have publicly announced disruptions to their planned and ongoing clinical trials due…
By
Johnson & Johnson’s single-shot Covid-19 vaccine best used to control outbreak, while Novavax’s vaccine shows better overall protection
With Johnson & Johnson (J&J) and Novavax, two more companies presented Covid-19 vaccine efficacy data last week. With an efficacy…
By